Aclaris Therapeutics, Inc. (ACRS) Company Profile
We are a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Our lead drug candidate, A-101 Topical Solution, is a proprietary high-concentration hydrogen peroxide topical solution that we are developing as a prescription treatment for seborrheic keratosis, or SK, a common non-malignant skin tumor. We have completed three Phase 2 clinical trials of A-101 in over 300 patients with SK. In these trials, following one or two applications of A-101, we observed clinically relevant and statistically significant improvements in clearing SK lesions on the face, trunk and extremities of the body. In the first quarter of 2016, we initiated two multi-center, double blind Phase 3 clinical trials and one open label Phase 3 clinical trial of A-101 in patients with SK.
News about ACRS
Aclaris Therapeutics (ACRS) Earns Daily Media Impact Score of 0.11
News headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog so...Read More>>>
3 Things In Biotech, June 10: Can CTI Salvage Bad News?
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. CTI Biopharma falters in non-Hodgkin lymphoma Compa...Read More>>>
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Aclaris Therapeutics (ACRS) Share Pric
Headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in ...Read More>>>
The 20% Pass-Through Deduction: Where Do We Stand Now?
&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-947019744&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/947019744/960x0.jpg?fit=scale&q; data-height=&q;636&q; data-width=&q;960&q;&g; U.S. President Donald Trump speaks duri...Read More>>>
Verrica Pharmaceuticals Files For $86 Million IPO
Quick Take Verrica Pharmaceuticals (VRCA) intends to sell shares of its common stock for gross proceeds of $86.3 million from a U.S. IPO, according to an S-1 registration statement. The firm is developing therapies for common skin diseases. The co...Read More>>>